Atopic Dermatitis Treatment Market
Atopic Dermatitis Treatment Market Size, Share & Trends Analysis Report, By Drug Class (Topical Therapies, Systemic Therapies, Adjunctive & Supportive Therapies), By Route of Administration (Topical, Oral, Injectable), By End User (Hospitals, Dermatology Clinics, Homecare Settings), Forecast Period (2026–2035)
Industry Overview
Atopic dermatitis treatment market size was valued at $13.2 billion in 2025 and is projected to reach $34.4 billion by 2035, expanding at a CAGR of 10.1% during 2026 to 2035. The market growth is primarily driven by the increasing prevalence of chronic inflammatory skin disorders and the rising demand for targeted therapies such as biologics and JAK inhibitors. According to the World Health Organization, skin diseases affect approximately 900 million people globally, highlighting the substantial patient pool for dermatological treatments. Additionally, the International Federation of Pharmaceutical Manufacturers & Associations reports growing investments in immunology pipelines, particularly in chronic diseases such as eczema and psoriasis. The increasing adoption of advanced therapies, coupled with improved diagnosis rates, is accelerating market expansion. Hospitals and dermatology clinics remain key end users, while home care settings are gaining traction due to patient convenience and availability of topical therapies. Rising healthcare expenditure, supported by the OECD, where healthcare accounts for over 9% of GDP globally, further supports the growth of the atopic dermatitis treatment market.
Market Dynamics
Driver: Rising Prevalence of Chronic Skin Disorders and Biologic Adoption
The increasing prevalence of atopic dermatitis and related inflammatory skin conditions is a major growth driver for the market. According to the World Health Organization, eczema affects up to 20% of children and 10% of adults globally, creating sustained demand for effective treatments. This growing patient pool is driving pharmaceutical companies to invest heavily in biologics and targeted therapies. Regulatory support is also accelerating growth. The U.S. Food and Drug Administration has approved several advanced therapies, including biologics and JAK inhibitors, improving treatment outcomes for moderate-to-severe cases. Companies such as Sanofi and Regeneron Pharmaceuticals are expanding indications for biologics like Dupixent, increasing market penetration. Additionally, rising healthcare spending and improved access to dermatology care are boosting adoption rates globally, particularly in emerging economies.
Challenge: High Treatment Costs and Limited Accessibility
Despite strong growth, the market faces challenges related to the high cost of advanced therapies. Biologic treatments and JAK inhibitors are significantly more expensive than traditional topical therapies, limiting accessibility in low- and middle-income countries. Supply chain complexities and regulatory hurdles also pose challenges. According to the European Federation of Pharmaceutical Industries and Associations, drug development timelines remain lengthy and costly, impacting product availability and pricing. Additionally, reimbursement limitations and a lack of awareness in developing regions hinder market expansion. Companies are addressing these challenges through biosimilar development, pricing strategies, and partnerships aimed at improving accessibility.
Market Segmentation
- Based on the drug class, the market is segmented into topical therapies, systemic therapies, and adjunctive & supportive therapies.
- Based on the route of administration, the market is segmented into topical, oral, and injectable.
- Based on the end user, the market is segmented into hospitals, dermatology clinics, homecare settings.
Systemic Therapies Segment Leads the Market
The systemic therapies segment dominates the atopic dermatitis treatment market due to the increasing use of biologics and oral JAK inhibitors for moderate-to-severe cases. These therapies offer targeted mechanisms of action, improving treatment efficacy and patient outcomes. Between 2022 and 2026, companies have focused on expanding biologics portfolios and securing regulatory approvals. For instance, AbbVie expanded Rinvoq indications, while Pfizer advanced Cibinqo approvals across multiple regions. The growing preference for long-term disease management and reduced relapse rates further supports the dominance of systemic therapies.
Injectable Segment to Record Strong Growth
The injectable segment is expected to witness the fastest growth due to the increasing adoption of biologics. Injectable therapies provide sustained efficacy and are widely used in severe cases of atopic dermatitis. Technological advancements in drug delivery and rising investment in biologics are driving this segment. Pharmaceutical companies are focusing on expanding clinical trials and launching new injectable therapies, particularly in emerging markets.
Regional Outlook
The global atopic dermatitis treatment market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).
United States Leads the Market
The United States dominates the global market due to high healthcare expenditure and advanced healthcare infrastructure. According to the OECD, the U.S. spends over 16% of its GDP on healthcare, the highest globally. The presence of major pharmaceutical companies and strong regulatory support from the U.S. Food and Drug Administration further accelerates market growth. The increasing prevalence of eczema and high adoption of biologics contribute significantly to regional dominance.
China to Record Strong Growth
China is expected to witness the fastest growth due to expanding healthcare infrastructure and increasing awareness of dermatological conditions. According to the World Intellectual Property Organization, China leads in pharmaceutical patent filings, indicating strong innovation activity. Rising investments in healthcare and growing access to advanced therapies are driving market expansion. Additionally, increasing urbanization and environmental factors are contributing to higher incidence rates of skin diseases.
Competitive Landscape
The atopic dermatitis treatment market is highly competitive, characterized by the strong presence of global pharmaceutical companies and continuous innovation in biologics and targeted therapies. Leading players such as Sanofi, Regeneron Pharmaceuticals, AbbVie, Pfizer, and Pfizer (Eucrisa) are focusing on expanding product portfolios, enhancing clinical pipelines, and strengthening global presence. Companies are investing in research and development, forming strategic partnerships, and expanding into emerging markets to maintain a competitive advantage.
Recent Developments
- In September 2025, Incyte received U.S. FDA approval for Opzelura for the treatment of mild to moderate atopic dermatitis in children aged 2 to 11 years, marking the first topical JAK inhibitor approved for pediatric use; in the same year, this milestone expanded therapeutic options for younger patients with limited treatment choices, strengthened the company’s dermatology portfolio, and represents a significant and direct advancement in the atopic dermatitis market by introducing an effective, non-steroidal treatment alternative.
- In February 2024, LEO Pharma announced its annual results for 2023, reporting strong revenue growth driven by its dermatology portfolio, particularly the expansion of Adtralza (Adbry), including new market launches and adolescent indication expansion; in the same period, the company highlighted continued investment in dermatology innovation and pipeline development, and while this represents a recent update, it is indirectly related to the atopic dermatitis market as it reflects commercial performance and strategic growth of an existing therapy rather than a new product approval or clinical breakthrough.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global atopic dermatitis treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies. Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Atopic Dermatitis Treatment Market Sales Analysis – Drug Class | Route of Administration | End User ($ Million)
- Atopic Dermatitis Treatment Market Sales Performance of Top Countries
1.1 Research Methodology
- Primary Research Approach
- Secondary Research Approach
1.2 Market Snapshot
- Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
2.2.1 Key Atopic Dermatitis Treatment Market Trends
2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Atopic Dermatitis Treatment Market
2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
- Market Determinants
3.1 Market Drivers
3.1.1 Drivers For Global Atopic Dermatitis Treatment Market: Impact Analysis
3.2 Market Pain Points and Challenges
3.2.1 Restraints For Global Atopic Dermatitis Treatment Market: Impact Analysis
3.3 Market Opportunities
3.3.1 Opportunities For Global Atopic Dermatitis Treatment Market: Impact Analysis
- Competitive Landscape
4.1 Competitive Dashboard – Atopic Dermatitis Treatment Market Revenue and Share by Manufacturers
- Atopic Dermatitis Treatment Product Comparison Analysis
- Top Market Player Ranking Matrix
4.2 Key Company Analysis
4.2.1 Sanofi (Dupixent)
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 Regeneron (Dupixent)
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 AbbVie (Rinvoq)
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 Pfizer (Cibinqo)
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 Pfizer (Eucrisa)
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration
- Global Atopic Dermatitis Treatment Market Sales Analysis by Drug Class ($ Million)
5.1 Topical Therapies
5.2 Systemic Therapies
5.3 Adjunctive & Supportive Therapies
- Global Atopic Dermatitis Treatment Market Sales Analysis by Route of Administration ($ Million)
6.1 Topical
6.2 Oral
6.3 Injectable
- Global Atopic Dermatitis Treatment Market Sales Analysis by End User ($ Million)
7.1 Hospitals
7.2 Dermatology Clinics
7.3 Homecare Settings
- Global Atopic Dermatitis Treatment Market Sales Analysis by Drug Class ($ Million)
8.1 Topical Therapies
8.2 Systemic Therapies
8.3 Adjunctive & Supportive Therapies
- Regional Analysis
9.1 North American Atopic Dermatitis Treatment Market Sales Analysis – Drug Class | Route of Administration | End User ($ Million)
9.1.1 United States
9.1.2 Canada
9.2 European Atopic Dermatitis Treatment Market Sales Analysis – Drug Class | Route of Administration | End User ($ Million)
9.2.1 UK
9.2.2 Germany
9.2.3 Italy
9.2.4 Spain
9.2.5 France
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Asia-Pacific Atopic Dermatitis Treatment Market Sales Analysis – Drug Class | Route of Administration | End User ($ Million)
9.3.1 China
9.3.2 Japan
9.3.3 South Korea
9.3.4 India
9.3.5 Australia & New Zealand
9.3.6 ASEAN Countries
9.3.7 Rest of Asia-Pacific
9.4 Rest of the World Atopic Dermatitis Treatment Market Sales Analysis – Drug Class | Route of Administration | End User ($ Million)
9.4.1 Latin America
9.4.2 Middle East and Africa
- Company Profiles
10.1 Amgen (Roklumis)
10.1.1 Quick Facts
10.1.2 Company Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.2 AnaptysBio (Rocatinlimab)
10.2.1 Quick Facts
10.2.2 Company Overview
10.2.3 Product Portfolio
10.2.4 Business Strategies
10.3 Arcutis Biotherapeutics (Zoryve)
10.3.1 Quick Facts
10.3.2 Company Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies
10.4 ASLAN Pharmaceuticals (Eblasakimab)
10.4.1 Quick Facts
10.4.2 Company Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.5 Astellas Pharma (Protopic)
10.5.1 Quick Facts
10.5.2 Company Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.6 Bausch Health (Orthovisc/Duobrii)
10.6.1 Quick Facts
10.6.2 Company Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies
10.7 Dermavant Sciences (Vtama)
10.7.1 Quick Facts
10.7.2 Company Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies
10.8 Eli Lilly (Ebglyss)
10.8.1 Quick Facts
10.8.2 Company Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.9 F. Hoffmann-La Roche (Lebrikizumab)
10.9.1 Quick Facts
10.9.2 Company Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies
10.10 Galderma (Nemluvio)
10.10.1 Quick Facts
10.10.2 Company Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
10.11 Incyte (Opzelura)
10.11.1 Quick Facts
10.11.2 Company Overview
10.11.3 Product Portfolio
10.11.4 Business Strategies
10.12 Kaken Pharmaceutical (Eckclock)
10.12.1 Quick Facts
10.12.2 Company Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies
10.13 Kyowa Kirin (KHK4083)
10.13.1 Quick Facts
10.13.2 Company Overview
10.13.3 Product Portfolio
10.13.4 Business Strategies
10.14 LEO Pharma (Adbry/Adtralza)
10.14.1 Quick Facts
10.14.2 Company Overview
10.14.3 Product Portfolio
10.14.4 Business Strategies
10.15 Maruho (Mitchga)
10.15.1 Quick Facts
10.15.2 Company Overview
10.15.3 Product Portfolio
10.15.4 Business Strategies
10.16 Novartis (Elidel)
10.16.1 Quick Facts
10.16.2 Company Overview
10.16.3 Product Portfolio
10.16.4 Business Strategies
10.17 Otsuka (Moizerto)
10.17.1 Quick Facts
10.17.2 Company Overview
10.17.3 Product Portfolio
10.17.4 Business Strategies
10.18 Sun Pharmaceutical (Levulan)
10.18.1 Quick Facts
10.18.2 Company Overview
10.18.3 Product Portfolio
10.18.4 Business Strategies
10.19 Torii Pharmaceutical (Corectim)
10.19.1 Quick Facts
10.19.2 Company Overview
10.19.3 Product Portfolio
10.19.4 Business Strategies
10.20 Viatris (EpiPen/Generic AD)
10.20.1 Quick Facts
10.20.2 Company Overview
10.20.3 Product Portfolio
10.20.4 Business Strategies
1. Global Atopic Dermatitis Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
2. Global Topical Therapies Atopic Dermatitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Systemic Therapies Atopic Dermatitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Adjunctive & Supportive Therapies Atopic Dermatitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Atopic Dermatitis Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
6. Global Topical Atopic Dermatitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Oral Atopic Dermatitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Injectable Atopic Dermatitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Atopic Dermatitis Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
10. Global Atopic Dermatitis Treatment for Hospitals Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Atopic Dermatitis Treatment for Dermatology Clinics Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Atopic Dermatitis Treatment for Homecare Settings Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Atopic Dermatitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
14. North America Atopic Dermatitis Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
15. North America Atopic Dermatitis Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
16. North America Atopic Dermatitis Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
17. North America Atopic Dermatitis Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
18. Europe Atopic Dermatitis Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
19. Europe Atopic Dermatitis Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
20. Europe Atopic Dermatitis Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
21. Europe Atopic Dermatitis Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
22. Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
23. Asia-Pacific Atopic Dermatitis Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
24. Asia-Pacific Atopic Dermatitis Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
25. Asia-Pacific Atopic Dermatitis Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
26. Rest of the World Atopic Dermatitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
27. Rest of the World Atopic Dermatitis Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
28. Rest of the World Atopic Dermatitis Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
29. Rest of the World Atopic Dermatitis Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
1. Global Atopic Dermatitis Treatment Market Share by Drug Class, 2025 Vs 2035 (%)
2. Global Topical Therapies Atopic Dermatitis Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
3. Global Systemic Therapies Atopic Dermatitis Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
4. Global Adjunctive & Supportive Therapies Atopic Dermatitis Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
5. Global Atopic Dermatitis Treatment Market Share by Route of Administration, 2025 Vs 2035 (%)
6. Global Topical Atopic Dermatitis Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
7. Global Oral Atopic Dermatitis Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
8. Global Injectable Atopic Dermatitis Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
9. Global Atopic Dermatitis Treatment Market Share by End User, 2025 Vs 2035 (%)
10. Global Atopic Dermatitis Treatment for Hospitals Market Research and Analysis by Region, 2025 Vs 2035 (%)
11. Global Atopic Dermatitis Treatment for Dermatology Clinics Market Research and Analysis by Region, 2025 Vs 2035 (%)
12. Global Atopic Dermatitis Treatment for Homecare Settings Market Research and Analysis by Region, 2025 Vs 2035 (%)
13. Global Atopic Dermatitis Treatment Market Share by Region, 2025 Vs 2035 (%)
14. U.S. Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
15. Canada Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
16. UK Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
17. France Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
18. Germany Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
19. Italy Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
20. Spain Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
21. Russia Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
22. India Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
23. China Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
24. Japan Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
25. South Korea Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
26. Australia & New Zealand Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
27. ASEAN Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
28. Rest of Asia-Pacific Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
29. Latin America Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
30. Middle East & Africa Atopic Dermatitis Treatment Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
